Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion
- PMID: 21949762
- PMCID: PMC3176812
- DOI: 10.1371/journal.pone.0024825
Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion
Abstract
MRCKα and MRCKβ (myotonic dystrophy kinase-related Cdc42-binding kinases) belong to a subfamily of Rho GTPase activated serine/threonine kinases within the AGC-family that regulate the actomyosin cytoskeleton. Reflecting their roles in myosin light chain (MLC) phosphorylation, MRCKα and MRCKβ influence cell shape and motility. We report further evidence for MRCKα and MRCKβ contributions to the invasion of cancer cells in 3-dimensional matrix invasion assays. In particular, our results indicate that the combined inhibition of MRCKα and MRCKβ together with inhibition of ROCK kinases results in significantly greater effects on reducing cancer cell invasion than blocking either MRCK or ROCK kinases alone. To probe the kinase ligand pocket, we screened 159 kinase inhibitors in an in vitro MRCKβ kinase assay and found 11 compounds that inhibited enzyme activity >80% at 3 µM. Further analysis of three hits, Y-27632, Fasudil and TPCA-1, revealed low micromolar IC(50) values for MRCKα and MRCKβ. We also describe the crystal structure of MRCKβ in complex with inhibitors Fasudil and TPCA-1 bound to the active site of the kinase. These high-resolution structures reveal a highly conserved AGC kinase fold in a typical dimeric arrangement. The kinase domain is in an active conformation with a fully-ordered and correctly positioned αC helix and catalytic residues in a conformation competent for catalysis. Together, these results provide further validation for MRCK involvement in regulation of cancer cell invasion and present a valuable starting point for future structure-based drug discovery efforts.
Conflict of interest statement
Figures
Similar articles
-
A novel small-molecule MRCK inhibitor blocks cancer cell invasion.Cell Commun Signal. 2014 Oct 5;12:54. doi: 10.1186/s12964-014-0054-x. Cell Commun Signal. 2014. PMID: 25288205 Free PMC article.
-
The CDC42 effector protein MRCKβ autophosphorylates on Threonine 1108.Small GTPases. 2020 Nov;11(6):451-460. doi: 10.1080/21541248.2018.1564472. Epub 2019 Jan 22. Small GTPases. 2020. PMID: 30667325 Free PMC article.
-
Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer.Cancer Res. 2018 Apr 15;78(8):2096-2114. doi: 10.1158/0008-5472.CAN-17-2870. Epub 2018 Jan 30. Cancer Res. 2018. PMID: 29382705 Free PMC article.
-
Opportunities and Challenges for the Development of MRCK Kinases Inhibitors as Potential Cancer Chemotherapeutics.Cells. 2023 Feb 7;12(4):534. doi: 10.3390/cells12040534. Cells. 2023. PMID: 36831201 Free PMC article. Review.
-
The actin-myosin regulatory MRCK kinases: regulation, biological functions and associations with human cancer.J Mol Med (Berl). 2014 Mar;92(3):217-25. doi: 10.1007/s00109-014-1133-6. Epub 2014 Feb 20. J Mol Med (Berl). 2014. PMID: 24553779 Free PMC article. Review.
Cited by
-
Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy.EMBO Rep. 2012 Oct;13(10):900-8. doi: 10.1038/embor.2012.127. Epub 2012 Sep 11. EMBO Rep. 2012. PMID: 22964758 Free PMC article. Review.
-
Rho/ROCK signaling in motility and metastasis of gastric cancer.World J Gastroenterol. 2014 Oct 14;20(38):13756-66. doi: 10.3748/wjg.v20.i38.13756. World J Gastroenterol. 2014. PMID: 25320513 Free PMC article. Review.
-
Identification of Kinases Responsible for p53-Dependent Autophagy.iScience. 2019 May 31;15:109-118. doi: 10.1016/j.isci.2019.04.023. Epub 2019 Apr 23. iScience. 2019. PMID: 31048145 Free PMC article.
-
Targeting Rho GTPase Signaling Networks in Cancer.Front Cell Dev Biol. 2020 Apr 3;8:222. doi: 10.3389/fcell.2020.00222. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32309283 Free PMC article. Review.
-
Cycloartane-3,24,25-triol inhibits MRCKα kinase and demonstrates promising anti prostate cancer activity in vitro.Cancer Cell Int. 2012 Nov 14;12(1):46. doi: 10.1186/1475-2867-12-46. Cancer Cell Int. 2012. PMID: 23151005 Free PMC article.
References
-
- Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009;26:273–287. - PubMed
-
- Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–269. - PubMed
-
- Wickman GR, Samuel MS, Lochhead PA, Olson MF. The Rho-Regulated ROCK Kinases in Cancer. In: van Golen K, editor. The Rho GTPases in Cancer. New York: Springer; 2010. pp. 163–192.
-
- Nakajima M, Hayashi K, Egi Y, Katayama K, Amano Y, et al. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol. 2003;52:319–324. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
